Flexion Therapeutics, Inc. (FLXN) has seen an increase of 73.36% in the premarket. However, the last trading session closed at $5.78 with an incline of 2.3%.
FLXN Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
On 1st October 2021, FLXN announced equity incentive awards totaling 6,315 restricted stock units to three new employees. The Compensation Committee of the Board of Directors authorized the grants. Subject to the new employee’s continuing service connection with FLXN, the restricted stock units vest over four years, with 25% of the shares vesting on each yearly anniversary of the appropriate vesting beginning date. Moreover, the restricted stock units are subject to the terms and circumstances of the Company’s 2013 Equity Incentive Plan.
Inclusion of ZILRETTA in American Academy of Orthopaedic Surgeons
On 2nd September 2021, ZILRETTA was included in the revised evidence-based clinical practise recommendations for the therapy of osteoarthritis. Moreover, experts recommend the use of intra-articular (IA) corticosteroids for individuals with symptomatic OA of the knee. An evaluation of 25 research evaluating IA corticosteroids led to the suggestion. A comparison of extended-release intra-articular steroid, of which ZILRETTA is the sole marketed medication, with immediate-release IA corticosteroids is included in its justification.
Expansion of Phase 1b Trial Investigating FX301 for the Management of Post-Operative Pain
On 25th August 2021, FLXN reported that FX301’s Phase has been expanded, according to the company. Firstly, FX301 promises to relieve post-operative pain. Secondly, an assessment of safety data from the single ascending dosage stage of the study by an independent Safety Monitoring Committee led to the company’s decision to move FX301 into the expansion cohort. Thirdly, an internal review committee of FLXN evaluated the program’s safety, systemic exposure, and effectiveness data and decided to move forward with it.
Publication of Results from Phase 2 Pharmacokinetics by FLXN
FLXN announced the findings of ZILRETTA on 9th August 2021. The researchers compared ZILRETTA’s plasma PK profile to that of immediate-release triamcinolone acetonide in crystalline suspension. However, they evaluated the drug’s safety and tolerability in patients with shoulder osteoarthritis (OA). 25 people with moderate to severe shoulder OA received a single ultrasound-guided intra-articular (IA) injection of ZILRETTA. Moreover, PK and safety characteristics were comparable to those seen in individuals with knee OA in Phase 3 trials. Lastly, the prolonged release of triamcinolone acetonide (TA) in the synovial fluid after an IA injection of ZILRETTA in the knee was likewise consistent with the plasma PK data from this research.
